It is worth noting that Michal Schwartz’s team used a PD-1 blocker antibody in their AD studies, the same molecule targeted by Merck & Co Inc.’s Keytruda (pembrolizumab), a medication that received FDA approval in early 2023 for cancer treatment [25]. This evidence concerns the gene PDCD1 and cancer.